These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 14571412)
1. Immunotherapy for prostate cancer. Fong L; Small EJ Semin Oncol; 2003 Oct; 30(5):649-58. PubMed ID: 14571412 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for prostate cancer. Fong L; Small EJ Curr Urol Rep; 2006 May; 7(3):239-46. PubMed ID: 16630528 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for prostate cancer. Fong L; Small EJ Curr Oncol Rep; 2007 May; 9(3):226-33. PubMed ID: 17430695 [TBL] [Abstract][Full Text] [Related]
4. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599 [TBL] [Abstract][Full Text] [Related]
6. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078 [TBL] [Abstract][Full Text] [Related]
7. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]. Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062 [TBL] [Abstract][Full Text] [Related]
9. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
10. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles. Nelson PS Ann N Y Acad Sci; 2002 Dec; 975():232-46. PubMed ID: 12538168 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system. Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443 [TBL] [Abstract][Full Text] [Related]
18. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cunha AC; Weigle B; Kiessling A; Bachmann M; Rieber EP Cancer Lett; 2006 May; 236(2):229-38. PubMed ID: 16046056 [TBL] [Abstract][Full Text] [Related]
19. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Slovin SF Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673 [TBL] [Abstract][Full Text] [Related]
20. Target antigens for prostate cancer immunotherapy. Saffran DC; Reiter RE; Jakobovits A; Witte ON Cancer Metastasis Rev; 1999; 18(4):437-49. PubMed ID: 10855787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]